Ikki kompaniya olimlari SARS-CoV-2 Omicron varianti ketma-ketligini, tanlangan virusli ketma-ketliklarni va plazmid klonlarini ishlab chiqishni tahlil qilishdi. Biz yangi Omicron SARS-CoV-2 vaksinalari 100 kundan kamroq vaqt ichida klinik sinovlarga kiritilishini kutamiz.
“Biz yangi Omicron COVID-19 variantiga qarshi kurashish uchun yangi vaksinalarni tez va samarali ishlab chiqish zarur deb hisoblaymiz. Biz tartibga soluvchi organlar bilan yaqindan hamkorlik qilamiz va ushbu vaksinani imkon qadar tezroq bozorga chiqarish uchun tegishli klinik tadqiqotlar va tartibga soluvchi tasdiqlarni izlaymiz. dedi Providence Therapeutics bosh direktori Bred Sorenson.
"Biz Providence bilan ushbu yangi Omicron variantli vaktsinasini tez ishlab chiqishni va bu vaktsina foydasini, xususan, hozirgi mRNK vaktsina davolash usullaridan foydalanish imkoniyati past bo'lgan hududlarga keltirishni intiqlik bilan kutmoqdamiz." sharhladi Kerri Blanchard, MD, PhD, Everest Medicines kompaniyasining bosh ijrochi direktori.
USHBU MAQOLADAN NIMA OLISH KERAK:
- “We look forward to rapidly developing this new Omicron variant vaccine with Providence, and bringing the benefit of this vaccine to those areas with lower accessibility to current mRNA vaccine treatments in particular.
- “We believe it is essential to develop new vaccines quickly and effectively to combat the new Omicron COVID-19 variant.
- We will work closely with regulatory bodies and seek the appropriate clinical studies and regulatory approvals to bring this vaccine to market as soon as possible.
